X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (17) 17
index medicus (17) 17
male (17) 17
oncology (17) 17
sarc14 (17) 17
female (14) 14
original reports (12) 12
adult (11) 11
aged (10) 10
middle aged (10) 10
treatment outcome (9) 9
antineoplastic agents - therapeutic use (8) 8
disease-free survival (8) 8
imatinib mesylate (7) 7
sarc2 (7) 7
adolescent (6) 6
young adult (6) 6
to24 (5) 5
antineoplastic agents - adverse effects (4) 4
cancer (4) 4
child (4) 4
diagnosis in oncology (4) 4
drug administration schedule (4) 4
piperazines - therapeutic use (4) 4
sarc16 (4) 4
tomography, x-ray computed (4) 4
trial (4) 4
aged, 80 and over (3) 3
antineoplastic agents - administration & dosage (3) 3
antineoplastic agents - pharmacokinetics (3) 3
benzamides (3) 3
european-organization (3) 3
gastrointestinal stromal tumors (3) 3
gastrointestinal stromal tumors - drug therapy (3) 3
kaplan-meier estimate (3) 3
mesylate (3) 3
mutation (3) 3
neoplasm metastasis (3) 3
pedi16 (3) 3
piperazines - adverse effects (3) 3
pyrimidines - adverse effects (3) 3
pyrimidines - therapeutic use (3) 3
resistance (3) 3
sarc13 (3) 3
sarcoma - drug therapy (3) 3
survival rate (3) 3
time factors (3) 3
united states (3) 3
angiogenesis (2) 2
antineoplastic combined chemotherapy protocols - therapeutic use (2) 2
benzamides - adverse effects (2) 2
benzamides - therapeutic use (2) 2
cells (2) 2
chemotherapy (2) 2
child, preschool (2) 2
cyclophosphamide - administration & dosage (2) 2
dermatofibrosarcoma protuberans (2) 2
disease progression (2) 2
doxorubicin - administration & dosage (2) 2
efficacy (2) 2
exons (2) 2
expression (2) 2
gastrointestinal stromal tumors - genetics (2) 2
gastrointestinal stromal tumors - pathology (2) 2
gene (2) 2
gic40 (2) 2
hema5 (2) 2
immunohistochemistry (2) 2
liposarcoma - drug therapy (2) 2
lymphatic metastasis (2) 2
piperazines - administration & dosage (2) 2
positron-emission tomography (2) 2
prognostic-factors (2) 2
protein kinase inhibitors - administration & dosage (2) 2
protein kinase inhibitors - adverse effects (2) 2
proto-oncogene proteins c-kit - genetics (2) 2
proto-oncogene proteins c-kit - metabolism (2) 2
pyridines - therapeutic use (2) 2
pyrimidines - administration & dosage (2) 2
radiotherapy, adjuvant (2) 2
risk assessment (2) 2
risk factors (2) 2
safety (2) 2
sarc15 (2) 2
sarcoma, alveolar soft part - drug therapy (2) 2
soft-tissue sarcomas (2) 2
solid tumors (2) 2
targets (2) 2
therapy (2) 2
tumors (2) 2
vincristine - administration & dosage (2) 2
1st-line treatment (1) 1
2nd primary malignancies (1) 1
3rd (1) 1
adolescence (1) 1
adolescents (1) 1
advanced thyroid-cancer (1) 1
aggressive fibromatosis (1) 1
aids-related opportunistic infections - blood (1) 1
aids-related opportunistic infections - drug therapy (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 07/2009, Volume 27, Issue 19, pp. 3133 - 3140
Journal Article
Journal Article
Journal Article
Journal Article
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2014, Volume 32, Issue 5, pp. 402 - 408
Purpose Kaposi's sarcoma (KS) is a disease of multifocal vascular proliferation that requires infection with KS herpes virus (KSHV/HHV-8). Activation of the... 
MESYLATE | CELLS | ANGIOGENESIS | ONCOLOGY | SAFETY | AUTOCRINE | GROWTH-FACTOR | VASCULAR-PERMEABILITY | EXPRESSION | PARACRINE | CHRONIC MYELOID-LEUKEMIA | AIDS-Related Opportunistic Infections - pathology | Benzamides - pharmacokinetics | Sarcoma, Kaposi - blood | United States | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | Proto-Oncogene Proteins c-kit - metabolism | Receptor, Platelet-Derived Growth Factor beta - genetics | Proto-Oncogene Proteins c-kit - antagonists & inhibitors | Sarcoma, Kaposi - drug therapy | Receptor, Platelet-Derived Growth Factor beta - antagonists & inhibitors | Benzamides - therapeutic use | Time Factors | Antineoplastic Agents - adverse effects | AIDS-Related Opportunistic Infections - genetics | Adult | Anti-HIV Agents - therapeutic use | Female | Proto-Oncogene Proteins c-kit - genetics | Antineoplastic Agents - pharmacokinetics | Piperazines - pharmacokinetics | Benzamides - adverse effects | Cytokines - blood | Receptor, Platelet-Derived Growth Factor beta - metabolism | Protein Kinase Inhibitors - pharmacokinetics | AIDS-Related Opportunistic Infections - drug therapy | Treatment Outcome | Piperazines - therapeutic use | Imatinib Mesylate | Piperazines - adverse effects | AIDS-Related Opportunistic Infections - blood | Disease Progression | Sarcoma, Kaposi - pathology | Pilot Projects | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Sarcoma, Kaposi - enzymology | AIDS-Related Opportunistic Infections - enzymology | Pyrimidines - adverse effects | Pyrimidines - pharmacokinetics | Aged | Mutation | Sarcoma, Kaposi - genetics | Index Medicus | Sarc16 | To24 | Nmel | Sarc14 | To11 | ORIGINAL REPORTS
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2009, Volume 27, Issue 5, pp. 812 - 826
Nearly 40 years ago, President Richard Nixon signed the National Cancer Act, mobilizing the country's resources to make the "conquest of cancer a national... 
TRIAL | STAGE BREAST-CANCER | WOMEN | MELANOMA | ONCOLOGY | ADVANCED THYROID-CANCER | PROSTATE-CANCER | LETROZOLE | PHASE-II | FINASTERIDE | SORAFENIB | United States | Humans | Central Nervous System Neoplasms - therapy | Male | Lung Neoplasms - therapy | Gastrointestinal Neoplasms - therapy | Research | Sarcoma - therapy | Breast Neoplasms - therapy | Urogenital Neoplasms - therapy | Genital Neoplasms, Female - therapy | Medical Oncology - trends | Financing, Government - trends | Female | Child | Bone2 | Bone1 | To19 | To18 | To17 | Asco Special | To16 | Dxst | To25 | To24 | To23 | To22 | To21 | To20 | Sarc8 | Sarc7 | Dxst3 | Hsr1 | Sarc6 | Hsr2 | Sarc5 | Dxst1 | Sarc4 | Dxst2 | Thor3 | Thor4 | Thor5 | Thor6 | Psc14 | Psc13 | Thor7 | Thor8 | Thor9 | Neur6 | Neur4 | Neur5 | Neur3 | Gic20 | Pedi2 | Pedi3 | Gic2 | Gic19 | Gic18 | Gic4 | Gic3 | Thor11 | Gic6 | Gic5 | Gic11 | Gic9 | Gic10 | Gic13 | Gic12 | Guc3 | Guc4 | Gic17 | Gic16 | Guc2 | Gync10 | Gync11 | Gic31 | Gic30 | Gync16 | Gync17 | Gync18 | Gync19 | Gync12 | Sarc14 | Gync13 | Sarc15 | Sarc12 | Sarc13 | Pedi10 | Gic24 | Gic23 | Gic26 | Gic25 | Gic27 | Hema7 | Gync20 | Hema8 | Hema5 | Hema6 | Gic40 | Gdln1 | Hema19 | Hema15 | Hema14 | Hema13 | Hema12 | Hema11 | Gic33 | To15 | Gic32 | To14 | Gic34 | Gic37 | Gic39 | Gic38 | Guc5 | Guc6 | Guc18 | Guc17 | Guc16 | Guc9 | Guc13 | Guc12 | Guc11 | Gync2 | Guc10 | Gync4 | Hema24 | Gync3 | Hema23 | Gync6 | Hema22 | Gync5 | Hema21 | Hema20 | Bc4 | Bc3 | Gync9 | Bc6 | Hnc3 | Hnc12 | Bc5 | Hnc4 | Hnc13 | Hnc10 | Hnc2 | Hnc11 | Hnc5 | Hnc6 | Hnc9
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.